A LC-MS method to quantify tenofovir urinary concentrations in treated patients

被引:23
作者
Simiele, Marco [1 ]
Carcieri, Chiara [2 ]
De Nicolo, Amedeo [1 ]
Ariaudo, Alessandra [1 ]
Sciandra, Mauro [1 ]
Calcagno, Andrea [1 ]
Bonora, Stefano [1 ]
Di Perri, Giovanni [1 ]
D'Avolio, Antonio [1 ]
机构
[1] Univ Turin, Lab Clin Pharmacol & Pharmacogenet, Dept Med Sci, Amedeo Savoia Hosp, I-10149 Turin, Italy
[2] Amedeo Savoia Hosp Turin, Dept Pharm, Turin, Italy
关键词
TDF; Urine; Mass spectrometry; HIV; HBV; Therapeutic drug monitoring; PERFORMANCE LIQUID-CHROMATOGRAPHY; HIV-INFECTED PATIENTS; SOLID-PHASE EXTRACTION; HUMAN PLASMA; MASS-SPECTROMETRY; TOXICITY; ASSAY; EMTRICITABINE;
D O I
10.1016/j.jpba.2015.05.001
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Tenofovir disoproxil fumarate is a prodrug of tenofovir used in the treatment of HIV and HBV infections: it is the most used antiretroviral worldwide. Tenofovir is nucleotidic HIV reverse trascriptase inhibitor that showed excellent long-term efficacy and tolerability. However renal and bone complications (proximal tubulopathy, hypophosphatemia, decreased bone mineral density, and reduced creatinine clearance) limit its use. Tenofovir renal toxicity has been suggested as the consequence of drug entrapment in proximal tubular cells: measuring tenofovir urinary concentrations may be a proxy of this event and it may be used as predictor of tenofovir side effects. No method is currently available for quantifying tenofovir in this matrix: then, the aim of this work was to validate a new LC MS method for the quantification of urinary tenofovir. Chromatographic separation was achieved with a gradient (acetonitrile and water with formic acid 0.05%) on an Atlantis 5 mu m T3, 4.6 mm x 150 mm, reversed phase analytical column. Detection of tenofovir and internal standard was achieved by electrospray ionization mass spectrometry in the positive ion mode. Calibration ranged from 391 to 100,000 ng/mL. The limit of quantification was 391 ng/mL and the limit of detection was 195 ng/mL. Mean recovery of tenofovir and internal standard were consistent and stable, while matrix effect resulted low and stable. The method was tested on 35 urine samples from HIV-positive patients treated with tenofovir-based HAARTs and did not show any significant interference with antiretrovirals or other concomitantly administered drugs. All the observed concentrations in real samples fitted the calibration range, confirming the capability of this method for the use in clinical routine. Whether confirmed in ad hoc studies this method may be used for quantifying tenofovir urinary concentrations and help managing HIV-positive patients treated with tenofovir. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:8 / 11
页数:4
相关论文
共 25 条
[1]  
[Anonymous], 2013, Guidance for industry # 213
[2]   Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function [J].
Calcagno, A. ;
de Requena, D. Gonzalez ;
Simiele, M. ;
D'Avolio, A. ;
Tettoni, M. C. ;
Salassa, B. ;
Orofino, G. ;
Bramato, C. ;
Libanore, V. ;
Motta, I. ;
Bigliano, P. ;
Orsucci, E. ;
Di Perri, G. ;
Bonora, S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) :1840-1843
[3]   A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients [J].
D'Avolio, Antonio ;
Sciandra, Mauro ;
Siccardi, Marco ;
Baietto, Lorena ;
de Requena, Daniel Gonzalez ;
Bonora, Stefano ;
Di Perri, Giovanni .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2008, 46 (06) :524-528
[4]   Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS [J].
Delahunty, T ;
Bushman, L ;
Fletcher, CV .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 830 (01) :6-12
[5]   Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring [J].
El Barkil, Mirna ;
Gagnieu, Marie-Claude ;
Guitton, Jerome .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 854 (1-2) :192-197
[6]  
Food and Drug Administration (FDA), 2013, Highlights of prescribing information
[7]   Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence [J].
Hall, Andrew M. ;
Hendry, Bruce M. ;
Nitsch, Dorothea ;
Connolly, John O. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (05) :773-780
[8]   Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection [J].
Jullien, V ;
Tréluyer, JM ;
Pons, G ;
Rey, E .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 785 (02) :377-381
[9]  
Kumar Agibothu K Hemanth, 2006, MedGenMed, V8, P53
[10]   Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir [J].
Labarga, Pablo ;
Barreiro, Pablo ;
Martin-Carbonero, Luz ;
Rodriguez-Novoa, Sonia ;
Solera, Carmen ;
Medrano, Jose ;
Rivas, Pablo ;
Albalater, Marta ;
Blanco, Francisco ;
Moreno, Victoria ;
Vispo, Eugenia ;
Soriano, Vincent .
AIDS, 2009, 23 (06) :689-696